BJH - volume 14, issue 6, october 2023
M. Beltjens MD, R. Lattenist MD, M. Rousseaux MD, P. Saussoy MD, PhD, X. Poiré MD, PhD, N. Straetmans MD, PhD
We report a patient developing mast cell leukaemia with subsequent multi-organ failure, three years after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome. Mast cell leukaemia is a very rare condition, accounting for <1% of all mastocytosis. In this article, we will discuss the atypical disease progression and treatment response, and diagnostic challenges.
(BELG J HEMATOL 2023;14(6):255–8)
Read moreBJH - volume 12, issue 1, february 2021
R. Lattenist MD, X. Poiré MD, PhD
The ASH 2020 annual meeting provided us with several contributions to the field of haematopoietic stem cell transplantation (HSCT). Post-transplant cyclophosphamide (PTCy) held a prominent place on the stage. This modality of graft-versus-host disease (GvHD) prophylaxis, initially developed in the haplo-identical HSCT setting, showed so much benefit that its use tends to spread throughout other types of donors. PTCy seems to be particularly investigated with the mission of improving outcomes in HSCT from mismatched unrelated donors (MMUD), which is of great interest for patients from underserved ethnicities lacking a matched donor. Management of chronic graft-versus-host disease (cGvHD) also had its share of improvement with the presentation of the results of the REACH3 study, comparing ruxolitinib to best available therapy. Reduced intensity conditioning (RIC) for myeloid malignancies got some attention with a boost to the support of its use for higher-risk myelodysplastic syndrome (MDS). We will also highlight an attempt to improve the efficacy of RIC in high-risk myeloid malignancies by the addition of venetoclax in a phase I study.
(BELG J HEMATOL 2021;12(1):33-7)
Read moreBJH - volume 11, issue Abstract Book BHS, february 2020
S. Servais MD, PhD, prof. F. Baron , C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, PhD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD
BJH - volume 10, issue 8, december 2019
T. Feys MBA, MSc, G. Roex , Y. Beguin MD, PhD, T. Kerre MD, PhD, X. Poiré MD, PhD, P. Lewalle MD, PhD, P. Vandenberghe MD, PhD, D. Bron MD, PhD, S. Anguille MD, PhD
Chimeric antigen receptor (CAR) T-cell therapy is a new cancer immunotherapy targeting specific cell surface antigens. This type of adoptive cell immunotherapy has been a breakthrough in the treatment of aggressive B-cell lymphoma and B-cell precursor acute lymphoblastic leukaemia (ALL) and is currently also being studied in other cancer types, including multiple myeloma and chronic lymphocytic leukaemia. This review will discuss the recent clinical developments and future perspectives of CAR T-cell therapy, with a focus on the clinical trials that led to the FDA and EMA approval of tisagenlecleucel (Kymriah®, Novartis) and axicabtagene ciloleucel (Yescarta®, Gilead) for the treatment of childhood/adult relapsed/refractory (r/r) B-cell precursor ALL and aggressive B-cell non-Hodgkin lymphoma.
(BELG J HEMATOL 2019;10(8):301–10)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
F. Van Obbergh MD, N. Vanlangendonck , A. Van Maanen , P. Van Muylder , A. Ferrant , C. Lambert MD, PhD, E. Van den Neste MD, PhD, D. Latinne , X. Poiré MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
A. Capes , F. Dall’Armellina , Y. Berners , L. Maindiaux , T. Connerotte MD, A. Camboni MD, PhD, P. Saussoy MD, PhD, J-P. Defour PhD, X. Poiré MD, PhD, N. Straetmans MD, PhD, M.C. Vekemans MD
BJH - 2018, issue Abstract Book BHS, february 2018
S. Dupriez , A. Ferrant , M.C. Vekemans MD, B. Brichard MD, PhD, L. Michaux MD, PhD, T. Connerotte MD, E. Van den Neste MD, PhD, C. Vermylen , L. Knoops MD, PhD, C. Graux MD, PhD, F. Duhoux MD, PhD, C. Lambert MD, PhD, X. Poiré MD, PhD, H.A. Poirel MD, PhD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
